Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating ...

Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics (AKTX) announces leadership ...

– Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 ...

PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, ...

Today’s executives are currently contending with what may be one of the most unsettled business environments of the past 40 years. Along with the lingering effects of the pandemic, a war in Eastern ...

Highway 2 reopens between Skykomish and Stevens Pass after flood clean-up Traffic is now flowing again on US-2 between Skykomish and Stevens Pass. Seattle neighbors frustrated by lack of action on ...

Tyler Lacoma has spent more than 10 years testing tech and studying the latest web tool to help keep readers current. He's here for you when you need a how-to guide, explainer, review, or list of the ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value ...

Akari’s PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action being developed for GA. “As part of the merger process, the boards of each company ...